Results 101 to 110 of about 186,086 (209)

Combined Immediate‐Release and Extended‐Release Formulation of Sodium Valproate Provides Stable Plasma Levels for Inhibition of Histone Deacetylation

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract A modified controlled‐release sodium valproate formulation (VAL001, test) was compared with an approved enteric‐coated tablet formulation (Absenor, reference). Pharmacokinetics and safety/tolerability were evaluated in healthy subjects to bridge with positive efficacy results from an early‐phase patient trial of valproate in combination with ...
Nikhil Ahuja   +8 more
wiley   +1 more source

Evolving Recommendations for Patient Populations Among Oncology Medicines: A Quantitative and Qualitative Analysis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
After a medicine has been tested in pivotal trials, regulators, health technology assessment (HTA) organizations, and professional societies make decisions about the patients best served by the medicine. This study assesses how the patient populations for oncology medicines (2010–2023) are defined (1) at trial, (2) regulatory submission, (3) upon ...
Milou A. Hogervorst   +5 more
wiley   +1 more source

Standardization of Suspension and Imaging Mass Cytometry Single‐Cell Readouts for Clinical Decision Making

open access: yesCytometry Part A, EarlyView.
ABSTRACT Suspension and imaging mass cytometry are single‐cell, proteomic‐based methods used to characterize tissue composition and structure. Data assessing the consistency of these methods over an extended period of time are still sparse and are needed if mass cytometry‐based methods are to be used clinically.
Ruben Casanova   +141 more
wiley   +1 more source

Comprehensive DSRCT multi‐omics analyses unveil CACNA2D2 as a diagnostic hallmark and super‐enhancer‐driven EWSR1::WT1 signature gene

open access: yes
Cancer Communications, EarlyView.
Florian Henning Geyer   +33 more
wiley   +1 more source

Clinical validation of a real‐time machine learning‐based system for the detection of acute myeloid leukemia by flow cytometry

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Machine‐learning (ML) models in flow cytometry have the potential to reduce error rates, increase reproducibility, and boost the efficiency of clinical labs. While numerous ML models for flow cytometry data have been proposed, few studies have described the clinical deployment of such models.
Lauren M. Zuromski   +10 more
wiley   +1 more source

Unraveling genotype–phenotype associations and predictive modeling of outcome in acute myeloid leukemia

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Acute myeloid leukemia (AML) comprises 32% of adult leukemia cases, with a 5‐year survival rate of only 20–30%. Here, the immunophenotypic landscape of this heterogeneous malignancy is explored in a single‐center cohort using a novel quantitative computational pipeline.
Artuur Couckuyt   +10 more
wiley   +1 more source

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo   +10 more
wiley   +1 more source

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

open access: yesEuropean Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy